Sollis Therapeutics

Sollis Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing non-steroid, non-opioid analgesics and anti-inflammatory medications for the treatment of lumbosacral radiculopathy, sciatica, and other neuropathic pain syndromes. Founded in 2017 and headquartered in Columbus, Ohio, the company is advancing its first product, an extended-release combination drug designed for targeted local delivery. This medication aims to provide effective relief from sciatica and similar pain conditions, addressing a significant unmet need in pain management. Through its innovative approach, Sollis Therapeutics seeks to enhance therapeutic options available to healthcare providers and improve patient outcomes.